Journal Home
Search for

Articles in Press

Return to articles in press list

Cardiac arrest with residual blindness after overdose of tessalon® (benzonatate) perles

Victor Cohen, BS, PHARMD, BCPS, CGPCorresponding Author Information, Samantha P. Jellinek, PHARMD, BCPS, CGP, Lindsay Stansfield, PHARMD, Henry Truong, MD, Cindy Baseluos, MD, John P. Marshall, MD

Received 22 May 2009; received in revised form 14 July 2009; accepted 29 August 2009. published online 06 November 2009.
Corrected Proof

Abstract 

Background: The extent to which benzonatate (Tessalon®), a structurally similar agent to other local anesthetics including tetracaine and procaine, poses a risk to the public is not fully appreciated as it is still one of the most widely prescribed antitussives available. Objectives: To report a case of cardiac arrest with residual blindness after Tessalon® overdose, review its clinical manifestations, toxicology and management considerations, and describe the need for rational prescribing. Case Report: A 17-year-old woman with no previous medical history presented to the Emergency Department (ED) status post cardiac arrest. One to two hours prior, the patient had ingested at least 10 200-mg Tessalon® capsules as part of a suicide attempt. The patient was sedated, intubated, and given magnesium as prophylaxis against recurrent dysrhythmias. Emergent gastric lavage was performed and well tolerated. A 24-h hypothermia protocol with 6-h cooling period was initiated. Toxicological studies, chest radiograph, and a computed tomography scan of the head were all unremarkable. The patient was admitted to the Pediatric Intensive Care Unit for further work-up and supportive care. The patient was extubated and able to follow some commands 1 week post-admission. The patient developed blindness and experienced generalized confabulations, which did not resolve. Conclusion: Ingestion of Tessalon®, a seemingly innocuous and widely prescribed antitussive, may pose a risk to patients due to its potential for the rapid development of life-threatening adverse events and limited treatment options in the overdose setting. Rational prescribing and patient education is needed.

 Department of Pharmaceutical Services, Residency Training Program, Maimonides Medical Center, Brooklyn, New York

 Department of Emergency Medicine, Residency Training Program, Maimonides Medical Center, Brooklyn, New York

Corresponding Author InformationReprint Address: Victor Cohen, BS, PHARMD, BCPS, CGP, Department of Pharmaceutical Services, Maimonides Medical Center, 4802 Tenth Avenue, Brooklyn, New York 11219

PII: S0736-4679(09)00752-5

doi:10.1016/j.jemermed.2009.08.027